Disclosed herein are methods for using therapeutic compounds, for example BH3 mimetics such as MCL1 inhibitors, to treat patients that may have failed to respond to targeted or immunotherapy treatments. In several embodiments, methods for treating such patients include combining MCL1 inhibitors with immunotherapies to enhance immunotherapy treatment. For example, the combination of MCL1 inhibitors with immunotherapies is used to treat cancer, such as melanoma. In some embodiments, MCL1 inhibitory compounds and therapies may be useful in treating tissues or tumors having one or more MDSC cell expressing high levels of MCL1. In some embodiments, MCL1 and BCL2 inhibitory compounds and therapies comprising same may be used to treat one or more melanomas, for example cutaneous melanoma, melanoma subtypes selected from uveal, acral, and mucosal. In some embodiments, MCL1 inhibitory compounds and therapies comprising same may be used to treat one or more melanomas, for example uveal melanoma. In many embodiments the targeted cells or tissues may not have BRAF mutations.

Provided herein are, inter alia, compositions including recombinant oncolytic herpes simplex viruses that express SARS-CoV spike (S) protein and viral vectors including nucleic acid sequences encoding SARS-CoV S protein. The compositions are useful for eliciting antibodies to SARS-CoV. The compositions are contemplated to be particularly useful for methods of treating and preventing SARS coronavirus infections in cancer patients.

The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.

The disclosure provides, inter alia, methods and materials involved in treating cancer using a p53 vaccine in combination with a PD-1 pathway inhibitor.

The present application discloses a method of treating cancer, including administering to a person suffering from cancer or in remission from cancer, an antigen presenting cell loaded with an immunogenic CD4 T cell activating antigen and a CD8 T cell activating neoantigen specific for the cancer.

A delivery system for delivering water-soluble components and water-insoluble components of whole-cell components using nano-sized or micro-sized particles, and a use of which in preparing vaccines for preventing and treating cancer. The whole-cell components delivery system consisting of a nano-sized or micron-sized particle and whole-cell components loaded on the particle, the whole-cell components are water-soluble components and water-insoluble components of a whole cell in a cell or tissue. The mutated proteins or peptides produced by cancer in cellular components are loaded on nanoparticles or micronparticles. These immunogenic substances generated by mutations in disease in whole-cell components can be used for cancer prevention and treatment and preparing vaccines for preventing and/or treating cancer.

The present disclosure provides T-cell modulatory multimeric polypeptides (T-Cell-MMPs) conjugated to a coronavirus epitope and comprising at least one immunomodulatory polypeptide (“MOD”) that may be selected to exhibit reduced binding affinity to a cognate co-immunomodulatory polypeptide (“Co-MOD”). By presenting the coronavirus epitope and MOD to a T-cell, the T-Cell-MMP-coronavirus epitope conjugates are useful for modulating the activity (e.g., increasing proliferation or cytotoxic activity) of T-cells specific to the coronavirus peptide in an epitope selective/specific manner, and accordingly, for treating individuals with a coronavirus infection.

Provided is an antibody combination therapy with an anti-CD39 antibody and an adoptive cell therapy.

Disclosed herein are compositions comprising optimized consensus TERT antigens and methods for treating cancer and in particular immunogenic compositions that treat and provide protection against tumor.

Disclosed herein are compositions comprising optimized consensus TERT antigens and methods for treating cancer and in particular immunogenic compositions that treat and provide protection against tumor.